Replit tackles the slop problem through a mix of specialized prompting, classification features built into its design systems ...

Replit CEO Amjad Masad says CEOs are showing up to meetings with prototypes, and product managers may just be "some of the ...

Aider is a “pair-programming” tool that can use various providers as the AI back end, including a locally running instance of Ollama (with its variety of LLM choices). Typically, you would connect to ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...

The last time I spoke about Replimune (REPL) it was with respect to a Seeking Alpha article entitled "Replimune: Scope Goes Beyond That of RP1 Oncolytic Targeting For Melanoma." With respect to this ...

If you are following Replimune Group (REPL) right now, you’re not alone. The company’s recent announcement about completing a Type A meeting with the FDA on its lead drug candidate, RP1, has put it ...

The latest trends and issues around the use of open source software in the enterprise. JetBrains has detailed its eighth annual Python Developers Survey. This survey is conducted as a collaborative ...

Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...